Eli Lilly's launch of Mounjaro in India in March 2025 was the first step of Tirzepatide in the country. In June 2025, the ...

Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and ...

Cipla and Lilly partner to distribute Yurpeak (tirzepatide) in India for type 2 diabetes and weight management. Broader ...

Under the agreement, Eli Lilly will continue to market tirzepatide under brand name Mounjaro, while Cipla will have the ...

Eli Lilly has signed a licensing deal with Cipla to market its blockbuster weight-loss drug under the brand name Yurpeak in ...

This collection of videos centers on rapid personal transformation through small, intentional shifts in mindset and daily ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

Eli Lilly's rival Novo Nordisk plans to retail both Ozempic and Wegovy in India as diabetes and weight-loss drugs, respectively.| Business News ...

Cipla shares drop 3.7% after Eli Lilly deal, but analysts see strong growth in India's obesity market—learn more about the ...

Cipla has partnered with Eli Lilly and Company (India) to distribute & promote Tirzepatide in India under a second brand name, Yurpeak, aiming to expand access to innovative treatments for chronic ...

US-based pharma giant Eli Lilly’s blockbuster weight-loss drug, Mounjaro, is set to expand its reach across India through a ...

Cipla and Eli Lilly India have announced an agreement to distribute a type 2 diabetes drug, tirzepatide, under the new brand ...